A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of N91115 in Healthy Subjects
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Cavosonstat (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms MAD
- Sponsors Nivalis Therapeutics
- 27 Jan 2017 Status changed from recruiting to completed.
- 18 Oct 2016 New trial record